NVG-111: a phase 1/2 trial of NVG-111 in relapsed or refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma and mantle cell lymphoma

A phase 1 trial testing NVG-111 in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04763083

Trial aim and background 

The aim of this trial is to test the safety of NVG-111 at different dose levels. Once a dose has been chosen, the study will test how effective the drug is in treating adults with CLL/SLL and mantle cell lymphoma that has either come back (relapsed) or not responded to previous treatment (refractory).

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Adults with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) mantle cell lymphoma (MCL), follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL which has not responded to (refractory), or has come back after (relapsed) treatment may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • University College London Hospital, London
  • Royal Marsden Hospital, London
  • The Christie NHS Foundation Trust, Manchester

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT04763083 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.